Rise and shine, everyone, another busy day is on the way. Our journey is made more tolerable today thanks to a bright and shiny sun enveloping the otherwise chilly Pharmalot campus. To keep warm, yes, we are quaffing a few welcome cups of stimulation, alternating between peppermint mocha and blueberry. Feel free to join us. What have you got to lose? Meanwhile, here are some tidbits. Hope you have a smashing day and, as always, we would like to remind you that we accept tips, encrypted messages, and secret dossiers from overseas …

Preliminary research suggesting some diabetes patients may be injecting medicine that has partially disintegrated is causing concern even as serious questions are raised about the research itself, the Associated Press writes. The study author, a pharmacist, bought 18 vials of insulin at several pharmacies and found, on average, the vials had less than half of what was listed on the label and none met a minimum standard. But the methods used to test the insulin are being questioned, and insulin makers, patient advocate groups, and diabetes experts say patients would be getting sick if the findings were accurate. The study was published in the Journal of Diabetes Science & Technology.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Jim Wilson should know something about gene therapy safety, given that he killed the first patient, Jesse Gelsinger, who had ornithine transcarbamylase deficiency with the replacement gene in an adenoviral vector that destroyed his liver. The irony is that Gelsinger could have survived simply by putting him on a protein sparing diet.

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy